STAT+: Major Indian generic drugmaker closes a U.S. facility after years of manufacturing problems
After a decade of manufacturing problems, a U.S. federal court ordered a unit of Wockhardt,…
Category: Pharmalot
STAT+: Pharmalittle: Murky online market for abortion pills is thriving; more ‘cash pay’ pharmacies decline insurance in the U.S.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA scolds Sun Pharma for allegedly backdating documents and fudging records for collecting drug samples
Sun Pharmaceutical, which is one of the largest purveyors of generic drugs, allegedly falsified various…
STAT+: Pharmalittle: Biden plan to shift cost of Covid-19 products to consumers; U.S. company to help with monkeypox shot production
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Medicare may eventually negotiate some drug prices, but Colorado still wants to import medicines from Canada
The Biden administration may have signed a law designed to lower prescription drug prices, but…
STAT+: Pharmalittle: FDA approves a gene therapy for a rare blood disorder; pharmacy chains ordered to pay $650 million over opioid crisis
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT+: ‘A blind eye’: NIH fails to ensure clinical trial results are reported and funds researchers who don’t file results
The U.S. National Institutes of Health failed to ensure that results of roughly half of…
STAT+: Pharmalittle: Endo files for bankruptcy protection due to opioid suits; first Zantac lawsuit dropped, giving GSK a boost
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Cepheid faces fresh criticism over the pricing of its TB diagnostics
A controversy has broken out over a diagnostic for tuberculosis that, until recently, had been…
STAT+: Pharmalittle: Activist investor targets Cardinal Health; 340B drug sales rose to $44 billion last year
Top of the morning to you, and a fine one it is. Crystal clear blue…
STAT+: Sales from controversial drug discount program rose to $44 billion last year
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $44…
STAT+: Pharmalittle: U.S. House passes drug-pricing legislation; U.K. is first country to approve a bivalent Covid shot
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Two children died after getting Novartis gene therapy; monkeypox vaccine maker warns about splitting doses
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices
The head of the U.S. Senate Finance Committee is seeking details from Amgen about the…
STAT+: Novartis reports two children died from acute liver failure after treatment with Zolgensma gene therapy
Two children have died from acute liver failure after being administered Zolgensma, a pricey gene…
STAT+: Pharmalittle: Judge rules Walgreens helped fuel San Francisco opioid crisis; U.S. plan to bottle monkeypox vaccine could take months
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent; U.S. to allow fractional doses of monkeypox vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: Pfizer to test a Lyme disease vaccine; only monkeypox drug in the U.S. is hard to access
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: For the second time, Pfizer tries a drug warranty in response to concerns over high costs
For only the second time, Pfizer is offering a warranty for a medicine that will…
STAT+: Pharmalittle: Medicare is poised to negotiate drug prices; Pfizer to pay $5.4 billion for Global Blood Therapeutics
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: PhRMA threatens Dems if drug-pricing bill passes; Novo plays down worries over obesity drug supplies
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: Lilly is ordered to pay $61 million for shortchanging the Medicaid drug rebate program
After nearly a decade of legal squabbling, Eli Lilly was ordered by a federal court…
STAT+: Civica Rx begins selling its first generic drug as it tries to overhaul the pharmaceutical supply chain
In the latest bid to address high prescription drug costs, a nonprofit plans to sell…
STAT+: Pharmalittle: AbbVie wins court opinion on Humira patent thickets; Alnylam heart disease drug succeeds in closely watched trial
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition
In a significant victory for AbbVie, a U.S. appeals court panel declined to revive a…
STAT+: Pharmalittle: West Virginia cities reach deal with wholesalers over opioid crisis; Democrats’ economic plan would raises taxes on pharma
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Major European research funders often fail to set policies or monitor progress on clinical trial transparency
Nearly two dozen major organizations that fund medical research in Europe often failed to set…
STAT+: Pharmalittle: Global demand for monkeypox vaccine will be hard to meet; Amgen dispute with IRS heats up
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pharma wages ‘hail Mary’ campaign to sink reconciliation bill; Moderna inks $1.74 billion deal with U.S. for Omicron shot
And so, another working week will soon draw to a close. Not a moment too…
STAT+: A ViiV deal to license its HIV prevention shot to poor countries runs into criticism
In a much ballyhooed move, ViiV Healthcare finalized a deal to license its long-acting injectable…
STAT+: Pharmalittle: AbbVie’s Allergan reaches $2 billion deal on opioid lawsuits; internal IQVIA documents question patient data privacy
Rise and shine, folks. Another busy day is upon us. And it looks to be…
STAT+: AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital
In an embarrassing episode for AbbVie, the company was reprimanded by a U.K. pharmaceutical industry…
STAT+: Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices
In his ongoing quest to probe pharmaceutical industry tax practices, the head of the U.S….
STAT+: Pharmalittle: Teva reaches $4.25 billion deal over its role in opioid crisis; feds probe Cassava over Alzheimer’s drug data
Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot…
STAT+: FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street
Once again, the U.S. Food and Drug Administration made a surprise move regarding an experimental…
STAT+: Pharmalittle: FDA will review Biogen ALS drug despite inconclusive results; Shkreli launches drug-discovery software company
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: ‘No magic bullet’: For drugmakers and the FDA, clinical trials on ultra-rare diseases pose thorny challenges
Walker Burger is beside himself with worry. The 33-year-old relies on an experimental medicine to…
STAT+: McDonald’s is criticized for leaving antibiotic reduction targets off its menu
Several advocacy groups have a beef with McDonald’s over its policy for using antibiotics in…
STAT+: Pfizer loses another court battle alleging the U.S. illegally limits use of copay assistance programs
In another setback for the pharmaceutical industry, a federal appeals court panel upheld a ruling…
STAT+: Pharmalittle: White House to launch effort for new generation of Covid shots; Indian court rejects bail pleas in Biocon bribery case
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Congress may miss deadline to pass FDA user-fee bill; ViiV is urged to lower price for its HIV prevention drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Roche CEO to step down next year; Gates Foundation withdraws financial support for malaria vaccine
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Biogen agrees to pay $900 million to settle whistleblower case alleging kickbacks and sham speaking events
After a decade of legal squabbling, Biogen has agreed in principle to pay $900 million…
STAT+: Pharmalittle: Pharma and advocacy groups differ on vaccine equity; EC says Illumina-Grail deal breached merger rules
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharma and advocacy groups offer competing visions for achieving vaccine equity during pandemics
Amid criticism over its approach to Covid-19, the pharmaceutical industry has issued a new “declaration”…
STAT+: Pharmalittle: FDA user-fee reauthorization bill hits a snag; USPTO takes a tougher stand toward drugmakers
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: Dozens of lawmakers urge HHS to fine drugmakers for curtailing discounts to a federal program
Dozens of lawmakers are demanding the Biden administration penalize drug companies that have curtailed discounts…
STAT+: Federal patent initiatives could cause ‘headwinds’ for drugmakers and their broad filings
For the second time this month, the U.S. Patent & Trademark Office has taken a…
STAT+: Contract research organization to transfer 4,000 beagles from facility cited for inhumane care
A contract research organization reached a final settlement with the U.S. government to transfer about…